Tetracaine Hydrochloride 0.5% · ophthalmic solution
Local Anesthetic
Same formulation, different label. Identical to Opticaine®. Choose on price and availability, not on the drug.
Approved uses
Topical anesthesia for ophthalmic procedures
1 drop topically in the eye(s) as needed
Corneal anesthesia is complete within 1 minute, with sensitivity back to baseline by 45 minutes.
OFF-LABELNot in the FDA label for this product
Corneal abrasion pain, short-term outpatient use
Preservative-free tetracaine 1%, up to every 30 minutes while awake for 24 hours (Waldman 2014); tetracaine every 30 minutes as needed for 24 hours (Shipman 2021)
Cochrane · very low certainty
Waldman 2014 (double-blind RCT, N=116) recorded no complications attributed to the anesthetic, no difference in persistent fluorescein uptake at 48 hours (23.9% vs 21.3%, difference 2.6%, 95% CI -14% to 20%) and no clinical difference in VAS pain, although patients rated it more effective than saline (7.7 vs 3.9 on a 0 to 10 scale). Shipman 2021 (double-blind RCT, 111 analyzed) found lower pain at the 24 to 48 hour visit (1 vs 8, 95% CI for the difference 6 to 8) and less hydrocodone use. The 2023 Cochrane review of topical ophthalmic anesthetics as a class (9 RCTs, 556 participants) graded the evidence very low certainty, concluded that it provides little or no certainty about efficacy for reducing ocular pain in the initial 24 to 72 hours and that the authors have very low confidence in it as a basis for recommending topical anesthetics for corneal abrasion pain, and found no evidence of a substantial effect on epithelial healing (unresolved defects after trauma RR 1.37, 95% CI 0.78 to 2.42, an estimate that crosses no effect) or on complications.
Contraindications
History of hypersensitivity to any component of this preparation.
0.5% (5 mg/mL) solution, 5 mL dropper bottle, 15 mL dropper bottle
Ester local anesthetic that blocks sodium ion channels required for initiation and conduction of neuronal impulses, producing surface anesthesia. Cleared by plasma pseudocholinesterases and nonspecific esterases in ocular tissue.
Warnings & Precautions
- Corneal injury with intracameral use: Not for injection or intraocular use. Do not use intracamerally because use may lead to damage of the corneal endothelial cells.
- Corneal toxicity: Prolonged use or abuse may lead to corneal epithelial toxicity and may manifest as epithelial defects which may progress to permanent corneal damage. Prolonged use of a topical ocular anesthetic may produce permanent corneal opacification and ulceration with accompanying visual loss.
- Corneal injury due to insensitivity: Patients should not touch the eye for at least 10 to 20 minutes after using anesthetic, as accidental injuries can occur due to insensitivity of the eye. The eyes will be insensitive for up to 20 minutes.
- For administration by healthcare provider: Indicated for administration under the direct supervision of a healthcare provider and not intended for patient self-administration.
Common Side Effects
Ocular adverse reactions identified following use include transient stinging, burning, and conjunctival redness; eye irritation; eye pain; and ocular discomfort. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Pregnancy: No adequate and well-controlled studies in pregnant women; no animal developmental or reproductive toxicity studies reported in the published literature.
Lactation: There are no data to assess whether it is excreted in human milk or its effects on milk production/excretion. Weigh the benefits of breastfeeding against the mother's clinical need and any potential adverse effects on the breastfed child.
Safety in the pediatric population has been demonstrated in clinical trials. Efficacy in pediatric patients has been extrapolated from adequate and well-controlled clinical trials in the adult population.